Introduction
Despite extensive efforts and significant progress in cancer treatment, therapeutic interventionsa re not yet satisfactory. Almost all available cytostatic drugs cause undesirable side effects, whereas drug resistance presents an additional problem. [1] [2] [3] In another field of medicine, an ongoing battle is being fought against malaria, ap arasitic disease causedb y Plasmodium species. [4, 5] Malaria still poses ag reat health and economic burden to theh ighly populated countries in the tropical and subtropical parts of the world. The need for new, effective antimalarials arises from several factors, including the absence of an effective vaccine, insufficient vectorc ontrol, and the emergence of multidrug-resistant Plasmodium strains. [6] [7] [8] The currently adopted approaches to the design of antiplasmodial compounds include the developmento fa nalogues of existingd rugs,resistance reversers, and novel compounds with new mechanismsofa ction. [6, 9] An umber of studies have shown ar elationship between cancer and malaria in regard to diagnostics, drug research, treatment, prevention, and epidemiology. [10] [11] [12] [13] Different classes of antimalarial drugs display direct or adjuvant activity against cancer cell lines, are knowna ss ensitivity reversers of resistant tumor cell lines or inhibitors of drug resistance development, or have synergistic action with knowna nticancer drugs. [14] [15] [16] [17] [18] [19] [20] Althought heir exact mode of action against canceri ss till not completely understood,v arious mechanisms have been proposed. [21] [22] [23] We report the synthesis of SAHAquines and related primaquine (PQ) derivatives. SAHAquines are novel hybrid compounds that combine moieties of suberoylanilide hydroxamic acid( SAHA), an anticancer agent with weak antiplasmodial activity,a nd PQ, an antimalarial drug with low antiproliferativea ctivity.T he preparation of SAHAquines is simple, cheap, and high yielding. It includes the followings teps:c oupling reaction between primaquinea nd ad icarboxylica cidm onoester, hydrolysis, an ew coupling reaction with O-protected hydroxylamine,a nd deprotection. SAHAquines 5a-d showeds ignificant reduction in cell viability.A mongt he three humanc ancer cell lines (U2OS, HepG2, and MCF-7), the most responsive were the MCF-7 cells. The antibodies against acetylated histone H3K9/H3K14 in MCF7c ells revealed as ignificant enhancement following treatment with N-hydroxy-N'-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}-pentanediamide( 5b). Ethyl (2E)-3-({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)prop-2-enoate (2b)a nd SAHAquines were the most active compounds againstboth the hepatic and erythrocytic stages of Plasmodium parasites, some of them at sub-micromolar concentrations.T he resultso fo ur research suggest that SAHAquines are promising leads for new anticancer and antimalarial agents.
Such observations prompted us, and others, to design and preparen ovel derivatives of known antimalarial drugs and evaluatet heir cytostaticp otential. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Our efforts have been focusedo np rimaquine (PQ), which is an old drug with many flaws (e.g.,induction of hemolytic anemia in individuals lacking glucose-6-phosphate dehydrogenase, quick metabolism, degradationt oi nactive carboxyprimaquine, altering the treatment outcomei nd ependence of CYP2 D6 enzymea ctivity) [35] but is currently the only available Plasmodium hypnozoitocide. [36] We previously showed that variousP Qd erivatives of amides, ureas, bis-ureas, semicarbazides, and acylsemicarbazide-type derivatives possessed significant cytostatic activity against a panel of cancerc ell lines or high selectivity towards the breast adenocarcinoma cell line (MCF-7). [24] [25] [26] [27] [28] [29] [30] On the other hand, cytostatic agents of different classes, including histoned eacetylase (HDAC)i nhibitors, have been shown to exert antiplasmodial activity. [6, [37] [38] [39] [40] [41] [42] Suberoylanilide hydroxamic acid (SAHA, vorinostat)w as the first marketed pan-HDAC inhibitor,a nd it was followed by other drugs from the same class (e.g.,r omidepsin, belinostat, and panobinostat. [43, 44] Their hydroxamic group chelates zinc ion found in the active site of Zn-dependent HDACs (classes I, II, and IV), and this leads to the accumulation of acetylated histones and other proteins. [45] HDACs were also identified as transcription regulators in P. falciparum. [46, 47] Out of five P. falciparum HDACs, three are Zn-dependent enzymes, prone to inhibition by SAHA, and thus representv iable targets for drug development. [48] Several studies have shownt he antimalarial activity of SAHA and related HDAC inhibitors. [49, 50] In this study,w ee mployed one of the classical medicinal chemists' tools-the combination of two pharmacophores in one molecule. [7, [51] [52] [53] [54] The concept of hybridd rugs is also av aluable strategy to overcome the limitations of ac ombined therapy,a st he resulting molecules could exhibit inhibitory activities on multiple targets. [55] The hybridc ompounds described here, SAHAquines, combine motifs of SAHA, an anticancer agent with weak antiplasmodial activity,a nd PQ, an antimalarial drug with low antiproliferative activity. Other here-reported PQ derivatives differ in the linker length/type and/or functional groups:c ompounds 2 are esters, compounds 3 are carboxylic acids, and compounds 4 and 6 are O-benzyl-a nd O-methylsubstituted hydroxamic acids. Similar to the knownH DACi nhibitors, hydroxamic acids 5 consist of acapping group (quinoline ring), al inker,a nd aZ n-binding group (hydroxamic acid) ( Figure 1 ). Given that hydroxamic acid is as trongb inding group for metal ions that might lead to poor selectivity and conferu ndesired properties, such as poor pharmacokinetics, [56, 57] we introduced other functional groups instead:a n ester,carboxylic acid, or O-protected hydroxamic group.
Herein, we report the synthesis of SAHAquines 5a-d as well as 20 novel PQ derivatives, their chemical characterization, the assessment of their cytostatic activity,a nd the evaluation of their activity against the erythrocytic andh epatic stages of Plasmodium.
Results and Discussion

Chemistry
The objective of our research was to prepare SAHAquines 5 and related PQ derivatives, which differ in the type/length of the spacera nd/or functional groups:c ompounds 2 are esters and compounds 3 are carboxylic acids, whereas compounds 4 and 6 are O-protectedh ydroxamic acids. Scheme 1s hows the synthetic pathway leading to derivatives 2-6.I nt he first reaction step, dicarboxylic acid monoesters 1a-e were coupled with PQ to give derivatives 2a-e by using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b ]pyridinium 3-oxid hexafluorophosphate( HATU) as the coupling reagent, alongw ith Hünig's base (N,N-diisopropylethylamine, DIEA). The following dicarboxylic acid monoesters were used:4 -methoxy-4-oxobutanoic acid( monomethyl hydrogen succinate) (1a), (E)-4-ethoxy-4-oxobut-2-enoic acid (monoethyl fumarate) (1b), 5-methoxy-5-oxopentanoic acid (monomethyl glutarate) (1c), 6-methoxy-6-oxohexanoic acid (monomethyl adipate) (1d), and 4-(methoxycarbonyl)benzoic acid (monomethyl terephtalate) (1e). Notably,a na nalogousc oupling reaction between PQ and monomethyl malonate failed in our hands. Amide formation between these two compounds by using thionyl chloride or benzotriazolide [58] was also unsuccessful and gave am ixture of products.C lassicala ctivation of the carboxylic group with thionyl chloride workedw ell with other dicarboxylica cid monoesters. Hydrolysis of 2a-e with lithium hydroxide afforded corresponding acids 3a-e,w hich were transformed into O-benzylhydroxamic acids 4a-e and O-methylhydroxamic acids 6a-e by means of O-benzyl-a nd O-methylhydroxylamine,r espectively.A gain, HATU/DIEA was used as the coupling system. Free hydroxamic acids 5a-d were obtained by catalytic hydrogenationo fO-benzyl derivatives 4a-e.S electived eprotection of the benzyl group in fumaricd erivative 4b failed. As ar esult of double-bondh ydrogenation, succinylhydroxamic acid 5a was obtained instead of fumarylhydroxamicacid.
All new compounds were fully characterized by conventional spectroscopy and analytical methods (IR, 1 HNMR, and 13 CNMR spectroscopy;MS; and elemental analyses). The data were consistentw ith the proposed structures and are given in short in To evaluatet he drug-like properties of our novel compounds, ac ommon set of physicochemical parameters were calculated:t opological polar surface area (TPSA), number of atoms, molecular weight (MW), partition coefficient (log P), number of H-bond donors (HBDs), number of H-bond acceptors (HBAs), and molar refractivity (MR). The parameters were calculated with Chemicalize.org software and are presented in Ta ble 1.
[59] All compounds 2-6 (except 4e,w hich showed minimal aberration) are fully in agreement with Lipinski's and Gelovani's rules for prospective small-molecule drugs (MW 500, log P 5, number of H-bondd onors 5, number of H-bond acceptors 10, TPSA < 140 2 ,M Rw ithin the range of 40 and 130 cm 3 mol
À1
,number of atoms 20-70). [60] Scheme1.Synthesis of PQ derivatives 2-6. Table 2 ). The data from Ta ble 2c learly indicatet hat the SAHAquines were the most potent in the selected cancer cell lines.T he IC 50 valuest owards MCF-7 cellsw ere in the low micromolar concentrations( 1.6-5.4 mm). Compounds from the other subclasses were, in general, less active than compounds 5.C ompounds 4d and 4e were the most effective O-benzylhydroxamic acids. In contrast, O-methylhydroxamic acids 6 exhibited weak activity,e xcept for succinic acid derivative 6a.A ll compounds from the ester series,e xcept 2c,s howed moderate activity,w hereas carboxylic acid derivatives 3a-e were practically inactive.
MCF-7c ells were sensitivet o1 5o ft he 24 tested compounds, namely, 5a-d, 2d, 2e, 4a, 4c-e,a nd 6a-d.S imilarr esults were obtained in our previous studies with various PQ derivatives. [24] [25] [26] [27] [28] [29] [30] On the otherh and, HepG2c ells were very robust and only responded towards 4d and compounds from subclass 5.T he non-cancer human cell line Hek293w as sensitive to 2b, 4e, 5a-d,a nd 6a but to al esser extent than the cancer cell lines. Selectivity indices ranged from 2t o1 2, depending on the tested compound and the cancer cell line employed.
To show the loss of MCF-7 cells following their exposure to the most potent compounds from subclasses 4 and 5,t hat is, 4e and 5b,w el abeled the cell nuclei with Hoechst 33342 and assessed the number of cells (Figure 2 ). The results from these studies complementt he data from the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Table 2) , showingacorrelation between significant loss of mitochondrial metabolic activity and ac oncentration-dependentd ecrease in the number of cells. Ar eduction in the number of MCF-7 cells was found for treatment over periods of 24 and 72 h. The IC 50 values for 5b and 4e obtainedf rom these assays were within ac omparable micromolar concentration range (5b:0 .5 and 1.6 mm; 4e:9 .0 and 11.5 mm). Determination of the number of cells is am ore direct wayo fs howing cell loss. As SAHAquines 5 with af ree hydroxamic acid have the potential to chelate metal ions in Zn-dependentH DACs and to increaset he content of acetylated histones, we performed a immunocytochemicala ssay for histonea cetylation. MCF-7 cells were treated with 5b and acetylated H3K9/H3K14w as measured. SAHA, PQ, and 4e were used as controls in the histone acetylation experiments. Indeed, the resultss how that 5b caused as ignificant accumulationo fa cetylated H3 histone (Figure 3 ), which suggested that HDAC inhibition was ap ossible contributingm echanism forS AHAquines 5 but not for the other PQ derivatives. Given that HDAC inhibition correlated with cellular histone acetylation but not with cell loss, we did not extensively study the kinetics of HDAC inhibition. [61] An indepth mechanistic study shouldb ep erformed to explain the mode of cell death caused by the SAHAquines.
Literature data on the antimalarialactivity of SAHA and related HDAC inhibitors [49, 50] prompted us to evaluate SAHAquines and their synthetic precursors for their in vitro activity against P. falciparum erythrocytic stages. The IC 50 values of SAHAquines 2-6 against the erythrocytic stage of two P. falciparum strains, 3D7 and Dd2, were determined (Table 3 ). In general, the 3D7 strain was more sensitive than the Dd2 strain. Again, the most active compounds were SAHAquines 5,t he hydroxamic acid subclass. Compound 5b had the lowest IC 50 value (0.4 mm for the Pf3D7 strain and 1.9 mm for the PfDd2 strain), followed by 5d (IC 50 = 0.6 and 1.2 mm,r espectively), 5c (IC 50 = 3.7 and 13.6 mm,r espectively), and finally 5a (IC 50 = 15.8 and 27.1 mm, respectively). Derivatives 2b and 2d were the most active compounds from the ester subclass, and 4e was the most active from the O-benzylhydroxamic acids. Carboxylica cids 3a-e were inactive.
We further evaluated the in vitro activity of compounds 2-6 against the hepatic stages of P. berghei. Twoc oncentrations of SAHAquines were tested:1a nd 10 mm.F or comparison, the same concentrations of PQ were included in the assay as a positive control (IC 50 = 8.4 AE 3.4 mm), and DMSO was used as a negative control( Figure4).
As shown in Figure 4 , only ester 2b and SAHAquines 5a-d were active against the P. berghei hepatic stages, whereas the other tested compounds were completelyi nactive. All compounds from hydroxamica cid subclass 5 exhibited strong antiplasmodiala ctivity at both concentrations tested, with IC 50 valuesr anging from 0.3 to 1.25 mm and without any noticeable effects on host-cell confluency ( Figure 5 ). Our resultss how that the free hydroxamic acid moiety was crucial for antiplasmodial activity,a sa ctivity was lost if this group was protected or replaced by ac arboxylic acid. The activity of compound 2b from the ester subclass was probablyd ue to the a,b-unsaturated carbonyl group (Michael acceptor moiety), which is capable of conjugate addition.
The relationship between antimalarial and anticancera ctivity is complex and is discussed in detail in ar eviewb yD uffy, Wade, and Chang. [62] Both main groups of existing antimalarial Figure 3 . MCF-7 cells were treatedwith PQ, SAHA, 4e,o r5b (1 mm)for 24 h. a) Representative fluorescencem icrographsofM CF-7 histone H3 acetylation (red) at lysine9/lysine 14 in response to treatments. Cells were incubated with primary antibody (rabbit anti-acetyl-Histone-H3 polyclonalantibody, 500 dilution) for 24 ha nd then with secondaryantibody (Alexa Fluor 647 goat anti-rabbit IgG À2mgmL À1 ;500 dilution) for 1hin the dark. Cells were imaged by using afluorescence microscope with aC Y5 filter.Fluorescence was analyzed in ImageJ. Scale bar represents 20 mm. b) Averages of fluorescence per cell AE SD (as fold increasei nu ntreated control = 1) from at least two independent experiments. * p < 0.05, t-test. agents, the quinolines and the sesquiterpene lactones,h ave a range of knowna nticancer properties that could either be distinct from or overlap with their antimalarial properties.A lthougho ur resultss how as imilarp attern of activity,i ts hould be noted that the activities of 5b and 5d are an order of magnitude highert owards the P. falciparum erythrocytic stage than towardst he tested cancer cell lines and the human embryonic kidney cells (Hek293). Having in mind that very good safety profiles are needed for antimalarial drugs,a st hey should be delivered, amongst others, to two particularly vulnerable populations, small children and pregnant women, [63] we are aware that our finding can only be as tartingp oint for the development of ac linically applicable antimalarial drug. As the antiplasmodial activities of compounds 2b and 5a-d were comparable to the activity of PQ, they might potentially replace PQ against PQ-resistant Plasmodium strains or in the treatment of glucose-6-phosphate dehydrogenase deficient patientsa nd poor metabolizers, but this hypothesis still remains to be evaluated. Notably,t he synthesis of SAHAquines is cheap and short (1-4 h) with good to excellent yields (43-97 %), which is beneficial for the development of antimalarial agents. [64] 
Conclusions
Four SAHAquines based on SAHA and PQ motifs and2 0o ther PQ derivatives were synthesized and evaluated in vitro against three human cancer cell lines andahuman embryonic kidney Figure 4 . Activity of compounds 2-6 against P. berghei hepatic stagesa tconcentrationsof1a nd 10 mm.Anti-infective activity( infections scale, bars) are shown.
ChemistryOpen 2018, 7,624 -638 www.chemistryopen.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim cell line. SAHAquines 5a-d displayed cytostatic activity at low micromolar concentrations. Af ew compounds from other subclasses were also effective,b ut less so than 5a-d.W es howed that the mosta ctive hydroxamic acid, that is, 5b,c aused as ignificant accumulationo fa cetylated histoneH 3K9/H3K14,a downstream target of class IH DACs. The results from the antiplasmodiala ctivity of SAHAquines against the erythrocytic stages of the 3D7 and Dd2 P. falciparum strains and against P. berghei hepatic stages correlated with their cytostatic activity.T he in vitro cytostatic and dual-stage antiplasmodial activity of SAHAquines suggest that these novel compounds could constitute ab asis for the development of effective anticancer or malaria prophylactic/curative agentsw ith improved potency and selectivity.
Experimental Section
GeneralMethods
Melting points were measured with aS tuart Melting Point (SMP3) apparatus (Barloworld Scientific, UK) in open capillaries. IR spectra were recorded with aF TIR PerkinElmer Spectrum One, and UV/Vis spectra were recorded with aL ambda 20 double-beam spectrophotometer (PerkinElmer,U K). All NMR ( 1 Ha nd 13 C) spectra were obtained at 25 8Cb yu sing an NMR Avance 600 spectrometer (Bruker,G ermany) at 300 and 150 MHz for 1 Ha nd 13 Cn uclei, respectively.C hemical shifts (d)a re reported in parts per million (ppm) relative to tetramethylsilane in the 1 Hs pectra and relative to [D 6 ]DMSO in the 13 Cs pectra (d = 39.51 ppm). Coupling constants (J)a re reported in hertz. Mass spectra were collected with aH PLC-MS/MS instrument (HPLC, Agilent Technologies 1200 Series;M S, Agilent Technologies 6410 Triple Quad). Mass determination was realized by using electrospray ionization (ESI) in the positive mode. Elemental analyses were performed with aC HNS LECO analyzer (LECO Corporation, USA). All compounds were routinely checked by TLC with Merck silica gel 60F-254 glass plates by using the following solvent systems:d ichloromethane/methanol 9:1, 9.5:0.5, and 9.6:0.4;c yclohexane/ethyl acetate 1:1; and cyclohexane/ethyl acetate/methanol 3:1:0.5. Spots were visualized by short-wave UV light and iodine vapor.C olumn chromatography was performed on silica gel 0.063-0.200 mm. All chemicals and solvents were of analytical grade and were purchased from commercial sources. PQ diphosphate, 4-methoxy-4-oxobutanoic acid (monomethyl succinate), (E)-4-ethoxy-4-oxobut-2-enoic acid (monoethyl fumarate), 5-methoxy-5-oxopentanoic acid (monomethyl glutarate), 6-methoxy-6-oxohexanoic acid (monomethyl adipate), 4-(methoxycarbonyl)-benzoic acid (monomethyl terephtalate), DIEA, HATU, O-benzylhydroxylamine, O-methylhydroxylamine, triethylamine, MTT,c isplatin (Cis), and Hoechst 33342 were purchased from Sigma-Aldrich; rabbit anti-acetyl-Histone-H3 polyclonal antibody was purchased from Millipore, Alexa Fluor 647 goat anti-rabbit IgG was purchased from Life Te chnologies, and SAHA was acquired from Cayman Chemicals. PQ was prepared from PQ diphosphate prior to use. All reactions with PQ were performed under light-protected conditions.
Synthesis
GeneralProcedure for the Preparation of Esters 2a-e
Method A: As olution of dicarboxylic acid monoester 1a-e (1.4 mmol), HATU (0.532 g, 1.4 mmol), and DIEA (0.362 g, 2.8 mmol) in dichloromethane (8 mL) was stirred at room temperature. After 10 min, as olution of PQ (0.401 g, 1.5 mmol) in dichloromethane (7 mL) was added. The mixture was stirred at room temperature for 1h and was then concentrated under reduced pressure. The residue was dissolved in ethyl acetate and extracted with brine (3 ). The organic layer was dried with sodium sulfate, filtered, and concentrated under reduced pressure.
Method B: As olution of dicarboxylic acid monoester 1a-e (1.8 mmol) in thionyl chloride (7 mL) was kept overnight and concentrated under reduced pressure. The residue was triturated with dichloromethane (2 ), and the solvent was evaporated again. A solution of PQ (0.401 g, 1.5 mmol) and Et 3 N( 0.152 g, 1.5 mmol) in dichloromethane (8 mL) was added dropwise to the carboxylic acid chloride dissolved in dichloromethane (10 mL). The mixture was stirred at room temperature for 1h and extracted with brine (3 ). The organic layer was dried with sodium sulfate, filtered, and concentrated under reduced pressure. General procedure for the preparation of carboxylic acids 3a-e:A solution of lithium hydroxide monohydrate (0.126 g, 3mmol) in water (10 mL) was added to asolution of ester 2 (6 mmol) in methanol (10 mL). The mixture was stirred at room temperature for 1h. Methanol was evaporated under reduced pressure, and the aqueous residue was neutralized with 10 %H Cl and extracted with dichloromethane (3 ). The organic layer was dried with sodium sulfate, filtered, and concentrated under reduced pressure. 3308, 2941, 2864 1727, 1691, 1636, 1613, 1575, 1519, 1454, 1422 General procedure for the preparation of O-benzylhydroxamic acids 4a-e:As olution of acid 3 (0.6 mmol), DIEA (0.155 g, 1.2 mol), and HATU (0.228 g, 0.6 mmol) in dichloromethane (6 mL) was stirred at room temperature. After 10 min, O-benzylhydroxylamine hydrochloride (0.112 g, 0.7 mmol) and Et 3 N( 0.071 g, 0.7 mmol) were added. The mixture was stirred at room temperature for 2h and concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and extracted with brine (3 ). The organic layer was dried with sodium sulfate, filtered, and concentrated under reduced pressure. , 1H,1 4), 6.13 (d, J = 8.8 Hz, 1H,7 ), 4.77 (s, 2H,7 '), 3.82 (s,  3H,1 7) , 3.62-3.56 (m, 1H,5 ), 3.08-3.04 (m, 2H,2 ), 2.04 (t, J = 7.4 Hz, 2H,4 '), 1.95 (t, J = 7.3 Hz, 2H,2 '), 1.74- 1.43 (m, 6H,3 ',3 ,4 3367, 3325, 3187, 2960, 2931, 2857, 1738, 1677, 1634, 1614, 1518,  1455, 1387, 1219, 1203, 1170, 1157, 1052, 1033, 821, 790 General procedure for the preparation of SAHAquines 5a-d:As uspension of O-benzylhydroxamic acid 4 (0.27 mmol) and 10 %P d/C (20 mg) in methanol (7 mL) was stirred at room temperature for 2-4h under ah ydrogen atmosphere. The catalyst was filtered off, and the mother liquor was concentrated under reduced pressure. , 1H,1 4) General procedure for the preparation of O-methylhydroxamic acids 6a-e:Asolution of corresponding acid 3 (0.2 mmol), DIEA (0.052 g, 0.4 mmol), and HATU (0.076 g, 0.2 mmol) in dichloromethane (5 mL) was stirred at room temperature. After 10 min, Omethylhydroxylamine hydrochloride (0.020 g, 0.24 mmol) and Et 3 N (0.024 g, 0.24 mmol) were added. The mixture was stirred at room temperature for 2h and was then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (8 mL) and extracted with water (3 ). The organic layer was dried with sodium sulfate, filtered, and concentrated under reduced pressure. 
3-({4-
[
Biological Evaluation
Cell viability:A ll synthesized compounds were first screened for their inhibition of mitochondrial metabolic activity by using the MTT assay. [65] Mitochondrial metabolic activity correlates with cell viability.T he following cell lines were tested:U 2OS, HepG2, MCF-7, and Hek293 cells. The compounds were dissolved in DMSO (3 10 À3 m)a nd stored at À20 8C. The cells were seeded at ad ensity of 3000 cells per 200 mLi na96-well plate (Sarsted) in triplicate and grown in Dulbecco'sm odified Eagle medium with 4500 mg L À1 glucose (DMEM-high glucose) (Lonza) containing 10 %f etal bovine serum (FBS) (Gibco), 100 UmL À1 penicillin, and 100 mgmL À1 streptomycin (Sigma-Aldrich). The next day,t he medium was aspirated and cells were treated for 72 h. Only the compounds that led to more than a4 0% reduction in mitochondrial metabolic activity at ac oncentration of 5 10 À5 m were selected for further analysis. The following concentrations of selected compounds were used:5 ,a nd 0.3 10 À3 %) in DMEM was considered as an egative control. Cisplatin, PQ, and SAHA were used as positive controls. After 72 ho fi ncubation in the presence of selected compounds, media were aspirated and MTT (0.5 mg mL À1 ;4 0mLp er well) was added, and the cells were incubated for 4h 37 8C. Media were aspirated and formazan crystals were dissolved in DMSO (170 mLp er well). The absorbance was measured on am icroplate reader (Promega) at l = 560 nm. The IC 50 values (concentration required to decrease viability by 50 %) were calculated by using nonlinear regression on the sigmoidal dose-response plots and are expressed as mean AE SD of two independent experiments. MCF-7 cell labeling with Hoechst 33342:F luorescent dye Hoechst 33342 was used to determine the total number of cells. MCF-7 cells were seeded at ad ensity of 3000 cells per 100 mL( 72 ht reatment) or 6000 cells per 100 mL( 24 ht reatment) in a9 6-well plate (Corning Inc.). Cells were grown in triplicate in DMEM containing 10 %F BS (Wisent), 100 UmL À1 penicillin, and 100 mgmL À1 streptomycin (Thermo Fischer). The next day,c ells were treated with SAHAquines 4e and 5b,S AHA, PQ, and cisplatin in ten different concentrations ranging from 5 10 À5 to 1 10 À9 m.A fter 72 h, cells were stained with Hoechst 33342 (10 mm,1 0min). Cells were then imaged by using af luorescence microscope (Leica, DMI4000B). Results were calculated by using nonlinear regression on the sigmoidal dose-response plot and are expressed as mean AE SD of two independent experiments.
In vitro drug sensitivity assay against erythrocytic stages of P. falciparum:T he antiplasmodial activity of compounds 2-6 was tested in ad rug-sensitivity assay against two laboratory P. falciparum strains (3D7-chloroquine sensitive, Dd2-chloroquine-resistant) as described before by using the histidine-rich protein 2( HRP2) assay. [66, 67] In brief, 96-well plates were precoated with the tested compounds in at hreefold dilution before ring-stage parasites were added in complete culture medium at ah ematocrit of 1.5 %a nd a parasitaemia of 0.05 %. After 3days of incubation at 37 8C, 5% CO 2 and 5% oxygen, plates were frozen until analyzed by HRP2-ELISA. All compounds were evaluated in duplicate in at least two independent experiments. The IC 50 was determined by analyzing the nonlinear regression of log concentration-response curves using the drc-package v0.9.0 of Rv 2.6.1. [68] In vitro activity against P. berghei hepatic stages:C ompound activity on P. berghei infection of ah uman hepatoma cell line (HuH7) was assessed employing the luminescence-based method, as previously described. [69] Briefly,h epatic infection was determined by measuring the luminescence intensity of lysates of HuH7 cells infected with af irefly luciferase-expressing P. berghei line. HuH7 cells (1.0 10 4 per well) were seeded in 96-well plates the day before infection. One hour prior to infection, the medium was replaced by medium containing the appropriate drug concentrations. The addition of 1.0 10 4 sporozoites was followed by centrifugation at 1800 g for 5min and parasite infection load was measured 48 h after parasite addition by ab ioluminescence assay (Biotium, USA) using am ultiplate reader Infinite M200 (Tecan, Switzerland). The effect of the different treatments on the viability of HuH7 cells was assessed by the CellTiter-Blue assay (Promega, USA) according to the manufacturer's protocol. Nonlinear regression analysis was employed to fit the normalized results of the dose-response curves, and IC 50 values were determined using GraphPad Prism V5.0.
Immunocytochemistry for histone acetylation:M CF-7 cells were seeded at ad ensity of 5000 cells per coverslip in DMEM containing 10 %F BS, 100 UmL À1 penicillin, and 100 mgmL À1 streptomycin and were left for 24 ht oa dhere. Cells were treated with 4e, 5b,S AHA, or PQ (at 1 mm concentration) for 24 h. Following treatment, cells were fixed with 4% paraformaldehyde (10 min), then permeabilized using 0.1 %T riton X-100 (10 min). Blocking was performed using 10 %g oat serum in phosphate buffer saline (PBS) (1 h), followed by incubation with primary antibody (rabbit anti-acetyl-Histone-H3 polyclonal antibody 1/500;M illipore 06-559) for 24 hi na humidified chamber at 4 8C. Samples were washed with PBS (3 5min). Samples were then incubated with secondary antibody (Alexa Fluor 647 goat anti-rabbit IgG À2mgmL À1 1/500;L ife Te chnologies A21244) for 1h in the dark, after which they were washed with PBS (3 5min). Nuclei were labeled with Hoechst 33342 (10 mm,1 0min). Samples were mounted on microscope slides using Poly Aqua Mount (PolySciences) and were dried overnight before imaging with af luorescence microscope (Leica). Fluorescence intensity was quantified using ImageJ software, and the results are presented as means of fluorescence per cell AE SD (as fold increase in the untreated control = 1).
